DNA-PK inhibitor, M3814, as a radiation sensitizer in the treatment of neuroendocrine tumors

被引：0
|
作者：
Rychahou, Piotr [1 ]
Chauhan, Aman [2 ,3 ]
Chow, Zeta [1 ]
Izumi, Tadahidi [4 ]
Chen, Quan [5 ]
Lee, Eun Y. [6 ]
Napier, Dana [6 ]
Anthony, Lowell B. [2 ,3 ]
Cavnar, Michael J. [1 ]
Kunos, Charles [7 ]
Evers, B. Mark [1 ,3 ]
机构：
[1] Univ Kentucky, Dept Surg, Lexington, KY USA
[2] Univ Kentucky, Dept Internal Med Med Oncol, Lexington, KY USA
[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
[4] Univ Kentucky, Markey Canc Ctr, Dept Toxicol & Canc Biol, Lexington, KY USA
[5] Univ Kentucky, Dept Radiat Med, Lexington, KY USA
[6] Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY USA
[7] NIH, Washington, DC USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6402
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6402
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results.
    Van Triest, Baukelien
    Damstrup, Lars
    Falkenius, Johan
    Budach, Volker
    Troost, Esther
    Samuels, Michael
    Debus, Juergen
    Sorensen, Morten Mau
    Berghoff, Karin
    Strotman, Rainer
    van Bussel, Mark
    Goel, Sanjay
    Geertsen, Poul F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials
    Mau-Sorensen, M.
    van Bussel, M.
    Kuipers, M.
    Nielsen, D. L.
    Verheul, H. M.
    Aftimos, P.
    de Jonge, M. J. A.
    van Triest, B.
    Falkenius, J.
    Debus, J.
    Troost, E.
    Samuels, M.
    Sarholz, B.
    Budach, V.
    Goel, S.
    Locatelli, G.
    Geertsen, P. F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
    Romesser, Paul Bernard
    Holliday, Emma B.
    Philip, Tony
    Sarholz, Barbara
    Kuipers, Mirjam
    Rodriguez-Gutierrez, Almudena
    Diaz-Padilla, Ivan
    Miller, Eric David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
    Romesser, Paul Bernard
    Holliday, Emma B.
    Philip, Tony
    Garcia-Carbonero, Rocio
    Capdevila, Jaume
    Tuli, Richard
    Sarholz, Barbara
    Kuipers, Mirjam
    Rodriguez, Almudena
    Diaz-Padilla, Ivan
    Miller, Eric David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [25] DNA-PK inhibitor, M3814, is a potent inducer of inflammatory micronucleation in irradiated p53-deficient cancer cells: Implications for combination radio-immunotherapy
    Carr, Michael
    Zimmermann, Astrid
    Guo, Yige
    Liu, Xiaohong
    Steiner, Patrick
    Hahn, Susanne
    Zenke, Frank
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Selective DNA-PK inhibitor, M3814, boosts p53 apoptotic response to DNA double strand breaks and effectively kills acute leukemia cells: Implications for AML therapy
    Haines, Eric
    Zimmermann, Astrid
    Zenke, Frank
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2018, 78 (13)
  • [27] M3814, a DNA-dependent Protein Kinase Inhibitor (DNA-PKi), Potentiates the Effect of Ionizing Radiation (IR) in Xenotransplanted Tumors in Nude Mice
    Damstrup, L.
    Zimmerman, A.
    Sirrenberg, C.
    Zenke, F.
    Vassilev, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 940 - 941
  • [28] Targeting DNA-PK and ATM with miR-101 Sensitizes Tumors to Radiation
    Wang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S631 - S632
  • [29] Hypoxia-selective DNA-PK inhibitor
    Kyle, Alastair H.
    Baker, Jennifer H. E.
    Fryer, Karen H.
    Banadth, Judit
    Wang, Taixiang
    Porres, Soraya S.
    Mann, Sam E.
    Hynd, George
    Menear, Keith
    Minchinton, Andrew, I
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [30] A phase Ia/Ib trial of the DNA-dependent protein kinase inhibitor (DNA-PKi) M3814 in combination with radiotherapy in patients with advanced solid tumors.
    Van Triest, Baukelien
    Damstrup, Lars
    Falkenius, Johan
    Budach, Volker
    Troost, Esther
    Samuels, Michael
    Goddemeier, Thomas
    Geertsen, Poul F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345